Mosapride as a Pre-endoscopy Preparation in a Patient Receiving GLP-1 Receptor Agonist Therapy

Read full text Summarise with VIRAT
Authors: Kazuki Inoue, Toshiyuki Morisawa, K Iguchi, Shigeto Masuda, Daiki Fumihara, Megumi Takagi, Tomoya Sako, Kenji Momose, Keisuke Furumatsu
Cited by: 0
References: 10

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

We present the case of a 66-year-old man who underwent upper gastrointestinal endoscopy and developed significant gastric residue after treatment with a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) for type 2 diabetes. Despite prolonged fasting, large volumes of gastric residue persisted, thus impairing mucosal visualization. Instead of discontinuing GLP-1RA therapy, mosapride citrate was introduced as a gastroprokinetic agent. Three days before endoscopy, the patient received mosapride, which resulted in complete gastric clearance and optimal endoscopic visualization. This case suggests that mosapride may be an effective pre-endoscopic preparation to counteract GLP-1RA-induced delayed gastric emptying.

Fields of Study & Subjects

Gastrointestinal motility and disorders Diabetes Treatment and Management Gastrointestinal Bleeding Diagnosis and Treatment

Publication details

Journal / source
Internal Medicine
Volume
65
Issue
22
Pages
2994–2997
Publication date
30 March 2026
Language
EN